AKCA News and Press, Akcea Therapeutics Inc. From 05/14/20

TEGSEDI is the first antisense medicine available to patients in Spain for at-home subcutaneous injection Approval Issued by Ministry of Health of Spain Only Six Months After Submission BOSTON , May 14, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-o...

Ionis Pharmaceuticals ( IONS +0.9% ) affiliate Akcea Therapeutics ( AKCA -0.1% ) announces that it has received a letter-of-intent from the Pan-Canadian Pharmaceutical Alliance for reimbursement of Tegsedi (inotersen injection) for the treatment of stage 1 or stage 2 polyneuropath...

Akcea Therapeutics Canada Confirms Letter of Intent with Pan-Canadian Pharmaceutical Alliance for TEGSEDI™ (inotersen injection) Canada NewsWire OTTAWA, May 13, 2020 For distribution in Canada only           &...

The following slide deck was published by Akcea Therapeutics, Inc. in conjunction with their 2020 Q1 earnings Read more ...

BOSTON , May 7, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Carla Poulson has joined the company as senior vice president and chief human resources officer. In these roles, Ms. Poulson will...

Akcea Therapeutics, Inc. (AKCA) Q1 2020 Earnings Conference Call May 05, 2020, 16:30 ET Company Participants Angelyn Lowe - Executive Director, Corporate Communications & IR Damien McDevitt - CEO & Director Kyle Jenne - Chief Commercial Officer Alex Howarth - COO Con...

Image source: The Motley Fool. Akcea Therapeutics, Inc.   (NASDAQ: AKCA) Q1 2020 Earnings Call May 5, 2020 , 4:30 p.m. ET Operator Continue reading

Akcea Therapeutics (NASDAQ: AKCA ): Q1 GAAP EPS of -$0.42 beats by $0.04 . More news on: Akcea Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

BOSTON , May 5, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing medicines to treat patients with serious and rare diseases, today reported financial results for the...

New York, New York--(Newsfile Corp. - April 29, 2020) - Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf of shareholders of Akcea Therapeutics, Inc. (NASDAQ: AKCA). Akcea is a developm...